Exposure to atropinic drugs and frailty status

J Am Med Dir Assoc. 2015 Mar;16(3):253-7. doi: 10.1016/j.jamda.2014.11.017. Epub 2014 Dec 23.

Abstract

Background: Atropinic drugs can increase the risk of falls, cognitive impairment, and mortality in older patients; however, whether exposure to atropinic drugs is associated with frailty status remains unknown. Our aim was to assess the association between frailty status and exposure to atropinic drugs in a geriatric day hospital population.

Methods: We carried out a cross-sectional study that included all the patients consulting for the first time at the Geriatric Frailty Clinic for Assessment of Frailty and Prevention of Disability in Toulouse, France, from January 2013 to October 2013. Frailty was defined by 3 or more of Fried et al's criteria. Atropinic drugs were those with clinical antimuscarinic effect from the Anticholinergic Drug Scale (excluding drugs weighted 1 point and not listed by Durán et al) and from Laroche et al list (to include drugs marketed in France not present in the Anticholinergic Drug Scale). To explore a dose-effect relationship, we calculated the atropinic burden using the Anticholinergic Drug Scale weights. We performed logistic regression models adjusted for age, gender, comorbidities, being community dwelling or not, cognitive status, educational level, and polypharmacy (≥6 drugs).

Results: We included 437 patients (227 frail and 210 robust or prefrail). Exposure to at least one atropinic drug was associated with frailty (odds ratio 1.97, 95% confidence interval 1.10-3.53, P = .02). Due to a statistically significant interaction between age and atropinic burden, a dose-effect relationship for atropinic burden was explored in patients younger than 85 years, showing a significant association between atropinic burden score and frailty (P = .01). The Odds ratio for an atropinic burden greater than or equal to 3 versus 0 was 3.84, 95% confidence interval 1.43-10.34 (P < .01).

Conclusions: In a geriatric day hospital, population frailty is associated with a high atropinic burden.

Keywords: Frailty; anticholinergic drug; atropinic burden.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Cholinergic Antagonists / administration & dosage*
  • Cholinergic Antagonists / adverse effects*
  • Cross-Sectional Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Utilization*
  • Female
  • Frail Elderly*
  • France
  • Geriatric Assessment / methods*
  • Hospitals, University
  • Humans
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Needs Assessment
  • Risk Assessment
  • Statistics, Nonparametric

Substances

  • Cholinergic Antagonists